{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-016308","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2026-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.306021+00:00","generated_at":"2026-05-15T06:33:50.690984+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xtant Medical secures exclusive U.S. distribution rights for HEMOBLAST Bellows hemostat","bullets":["Paid Dilon a $5.0M exclusivity fee; no minimum purchase requirements.","Hired approximately 20 Dilon U.S. sales personnel to commercialize the product.","HEMOBLAST Bellows is an FDA-approved collagen/thrombin/chondroitin sulfate hemostatic powder.","Addresses estimated $2.0 billion global addressable market for hemostatic products.","Xtant to update FY2026 guidance upon Q1 2026 earnings release."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-016308","json":"https://secwatch.observer/filing/0001493152-26-016308.json","markdown":"https://secwatch.observer/filing/0001493152-26-016308.md","text":"https://secwatch.observer/filing/0001493152-26-016308.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000149315226016308/0001493152-26-016308-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000149315226016308/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:33:50.690984+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}